{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-009578","form_type":"8-K","ticker":"AIMD","cik":"0001014763","company_name":"Ainos, Inc.","filed_at":"2025-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.703594+00:00","generated_at":"2026-05-25T02:49:29.613268+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ainos reports FY2024 revenue $20,729, net loss $14.9M; AI Nose and VELDONA progress","bullets":["Revenue fell 83% YoY to $20,729; cost of revenues $52,595; gross loss narrowed to $31,866.","Net loss attributable to common shareholders $14.86M vs $13.77M in FY2023.","Cash and equivalents $3.89M as of Dec 31, 2024, up from $1.89M a year ago.","R&D expenses rose to $8.4M (including share-based comp); SG&A decreased to $5.4M.","Key milestones: AI Nose Flora second-gen clinical studies H1 2025; VELDONA Japan patent and Taiwan Tanabe partnership; IRB approval for Sjögren's trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-009578","json":"https://secwatch.observer/filing/0001493152-25-009578.json","markdown":"https://secwatch.observer/filing/0001493152-25-009578.md","text":"https://secwatch.observer/filing/0001493152-25-009578.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1014763/000149315225009578/0001493152-25-009578-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1014763/000149315225009578/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T02:49:29.613268+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}